See the DrugPatentWatch profile for symtuza
Yes, Symtuza Is a Single Tablet Regimen
Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) combines four antiretroviral agents into one fixed-dose tablet taken once daily. This complete regimen treats HIV-1 in adults and children weighing at least 35 kg, with or without food, alongside standard dosing guidelines.[1]
How Does Symtuza's Dosing Work?
Patients take one 800/150/200/10 mg tablet orally once daily. No additional HIV medications are needed for the core regimen, simplifying adherence compared to multi-pill options. Adjustments apply for renal or hepatic impairment.[1]
Why Choose a Single Tablet Over Multi-Pill Regimens?
Single-tablet regimens like Symtuza reduce pill burden, improving long-term compliance—key for viral suppression. Studies show higher adherence rates with STRs versus separate pills, lowering resistance risk.[2]
Who Makes Symtuza and When Do Patents Expire?
Janssen (a Johnson & Johnson company) developed and markets Symtuza, approved by the FDA in 2018. Key U.S. patents, including composition-of-matter for the combo, extend protection into the 2030s; check DrugPatentWatch.com for exact expiry dates and challenges.[3]
Common Patient Questions on Side Effects and Switches
Diarrhea, nausea, and headache occur most frequently. Long-term risks include renal issues from tenofovir and bone density loss. Patients switching from other regimens maintain viral control without a washout period.[1][2]
How Does Symtuza Compare to Other STRs Like Biktarvy or Cabenuva?
| Regimen | Components | Dosing | Key Differences |
|---------|------------|--------|-----------------|
| Symtuza | DRV/c/FTC/TAF | 1 tab daily | Boosted protease inhibitor; good for resistance history |
| Biktarvy | BIC/FTC/TAF | 1 tab daily | Integrase inhibitor; smaller pill, fewer food restrictions |
| Cabenuva | CAB + RPV | 2 injections monthly (after oral lead-in) | Long-acting injectable; no daily pills |
Symtuza suits those needing protease inhibitor backbone; Biktarvy is often first-line for fewer interactions.[2]
Sources:
[1] Symtuza Prescribing Information (FDA)
[2] DHHS HIV Guidelines
[3] DrugPatentWatch: Symtuza